Cosmos Health Signs LOI to Acquire Doc Pharma S.A., a European GMP Pharmaceutical Manufacturer, a Transformative Step Expected to Boost Assets, Profitability, Production Capacity, and Product Portfolio

Cosmos Health Inc. (NASDAQ: COSM) announced a non-binding letter of intent to acquire 100% of Doc Pharma S.A., a European GMP-licensed pharmaceutical manufacturer. The acquisition is expected to be immediately accretive, expanding Cosmos Health's asset base by approximately $24 million, adding $6.7 million in average annual revenue and $3.2 million in gross profit. The deal aims to deepen vertical integration, improve margins, expand production capacity, and strengthen the company's R&D capabilities. The transaction is subject to independent director review, fairness opinion, and shareholder approval.

06/11/2026, 3:31 PM • Benzinga

Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility

Cosmos Health Inc. purchased an additional $500,000 in Ethereum, bringing its total investment to $1.5 million under its $300 million digital assets facility, aiming to diversify its balance sheet and explore blockchain technology in healthcare.

10/10/2025, 8:00 AM • GlobeNewswire

Cosmos Health Expands Sky Premium Life Into $1Bn+ Kuwait Market; Signs Exclusive Distribution Agreement With Diyar United and Secures Initial Purchase Order of Over 65,000 Units

Cosmos Health's subsidiary SkyPharm signed an exclusive distribution agreement with Diyar United to market Sky Premium Life nutraceuticals in Kuwait, securing an initial purchase order of over 65,000 units in a market projected to reach $1.68 billion by 2030.

10/03/2025, 3:56 PM • GlobeNewswire

Cosmos Health Commences U.S. Operations, Entering $164B Nutraceuticals Market with Its Sky Premium Life Brand; Expects 75% Gross Margins and Strong Cash Flow, with NOOR Collagen Alone Projected to Generate Over $12M in Annualized Revenue

Cosmos Health enters the U.S. nutraceuticals market with its Sky Premium Life brand, launching NOOR Collagen and expecting 75% gross margins and over $12M in annualized revenue from the product.

09/22/2025, 8:00 AM • GlobeNewswire

Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units

Cosmos Health signed a distribution agreement with Scientific Pharmacy in Oman for Sky Premium Life food supplements, securing an initial purchase order of 42,000 units in the rapidly growing $7 billion GCC nutraceuticals market.

09/11/2025, 8:00 AM • GlobeNewswire

Cosmos Health Reports Q2 2025 Results; Continues Strong Growth with 11.7% Revenue Increase; On Track to Meet Profitability Targets with Gross Profit Up 53% to $3.21M in H1 2025

Cosmos Health reported Q2 2025 financial results with 11.7% revenue increase, gross profit up 53% to $3.21M in H1 2025, and continued progress towards profitability targets while expanding digital asset strategy.

08/18/2025, 12:45 PM • GlobeNewswire